icon fsr

文献詳細

雑誌文献

耳鼻咽喉科・頭頸部外科85巻7号

2013年06月発行

文献概要

特集 分子標的薬時代の耳鼻咽喉科診療―処方するとき,服用患者を診るときのポイント ≪頭頸部癌に対する分子標的薬治療≫

頭頸部癌に対する分子標的薬の将来展望―セツキシマブのほかには何があるのか

著者: 清田尚臣1

所属機関: 1神戸大学大学院医学研究科内科学講座腫瘍・血液内科学分野

ページ範囲:P.488 - P.492

文献購入ページに移動
POINT

●標的分子としてのerbBファミリーの可能性

●標的分子としてのVEGFの可能性

●erbBファミリーおよびVEGF以外の標的分子

参考文献

1)Vermorken JB, et al:Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
2)Machiels JP, et al:Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy:an open-label, randomised phase 3 trial. Lancet Oncol 12:333-343, 2011
3)Mitsudomi T, et al:Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
4)Maemondo M, et al:Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
5)Stewart JS, et al:Phase Ⅲ study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck[corrected]. J Clin Oncol 27:1864-1871, 2009
6)Shepherd FA, et al:Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
7)Soulieres D, et al:Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004
8)Siu LL, et al:Phase Ⅰ/Ⅱ trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck:a Princess Margaret Hospital phase Ⅱ consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25:2178-2183, 2007
9)Cohen EE, et al:Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck:a phase Ⅰ/Ⅱ study. Lancet Oncol 10:247-257, 2009
10)Slamon DJ, et al:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
11)Bang YJ, et al:Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
12)Kalyankrishna S, et al:Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24:2666-2672, 2006
13)de Souza JA, et al:A phase Ⅱ study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 18:2336-2343, 2012
14)Yang JC, et al:Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations(LUX-Lung 2):a phase 2 trial. Lancet Oncol 13:539-548, 2012
15)Argiris A, et al:Phase Ⅱ trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 29:1140-1145, 2011
16)Williamson SK, et al:Phase Ⅱ evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck:Southwest Oncology Group Study S0420. J Clin Oncol 28:3330-3335, 2010
17)Machiels JP, et al:Phase Ⅱ study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck:GORTEC 2006-01. J Clin Oncol 28:21-28, 2010
18)Schmitz S, et al:Phase Ⅱ study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck:clinical activity and molecular response(GORTEC 2008-02). Ann Oncol 23:2153-2161, 2012
19)Brooks HD, et al:Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117:2112-2119, 2011
20)Kwak EL, et al:Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010

掲載誌情報

出版社:株式会社医学書院

電子版ISSN:1882-1316

印刷版ISSN:0914-3491

雑誌購入ページに移動
icon up
あなたは医療従事者ですか?